N/A
N=20
The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI
Coronary Artery Disease
Bottom Line
View on ClinicalTrials.gov: NCT04316676 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Jan 2026
Primary outcome: Primary: Myocardial Blood Flow — 1.60; 0.96; 2.40 mL/g/min
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- PET-MPI Protocol (Diagnostic_test); CT-MPI (Diagnostic_test); Coronary CT angiography (CCTA) for CT-FFR calculation (Diagnostic_test); Regadenoson (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Emory University
- Primary completion
- Sep 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Myocardial Blood Flow |
1.60; 0.96; 2.40 | — |
| PRIMARY Coronary Flow Per CT-FFR |
1.29 | — |
| PRIMARY Sensitivity of Myocardial Perfusion Abnormalities Diagnosis |
100; 100 | — |
| PRIMARY Specificity of Myocardial Perfusion Abnormalities Diagnosis |
100; 94 | — |
| PRIMARY Area Under the Curve (AUC) for Detection of Myocardial Perfusion Abnormalities |
1.00; 0; 0.97 | — |
| PRIMARY Sensitivity of Coronary Stenosis Diagnosis |
67; 67; 100 | — |
| PRIMARY Specificity of Coronary Stenosis Detection |
100; 100 | — |
| PRIMARY Area Under the Curve for Detection of Coronary Stenosis |
0.83; 0.83; 1 | — |
Summary
The overall goal of this project is to compare the absolute quantification of myocardial perfusion done by using CT myocardial perfusion imaging (CT-MPI) and the coronary flow measured by using CT Fractional Flow Reserve analysis (CT-FFR) to the gold standard represented by PET myocardial perfusion imaging (PET-MPI).
Eligibility Criteria
Inclusion Criteria
- Referred for a clinically indicated CT-MPI for CAD assessment
- Must provide written informed consent prior to any study-related procedures being performed
- Must be willing to comply with all clinical study procedures
Exclusion Criteria
- Pregnant or nursing females. The possibility of pregnancy will be excluded by testing (serum or urine ßHCG) within 24 hours before study agent administration, or if the woman has previous surgical sterilization, or if the woman is post-menopausal, with minimum one (1) year history without menses.
- Currently taking or has taken within 48 hours the following excluded medications:
- ActoPlus Met (Pioglitazone + metformin)
- Avandamet (Rosiglitazone + metformin)
- Fortamet (metformin)
- Glucovance (Glyburide +metformin)
- Glucophage (metformin)
- Glucophage extended-release (XR) (metformin)
- Glumetza (metformin)
- Janumet (Sitagliptin + metformin)
- Metformin
- Metaglip (Glipizide + metformin)
- Riomet (metformin)
- Acute psychiatric disorder
- Unwilling to comply with the requirements of the protocol
- Previously entered this study
- Known hypersensitivity to iodinated contrast material, beta-blockers, or pharmaceutical stressors used in this study
- Suffers from claustrophobia
- Impaired renal function (GFR < 45 ml/min)
- Acute hypotension (<100 mm Hg systolic)
- 2nd or 3rd degree atrioventricular (AV) block
Data sourced from ClinicalTrials.gov (NCT04316676). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.